Acromegaly

Journal of Endocrinology

Volumn 226, Issue 2, 2015, Pages T141-T160

  Capatina, Cristina ^a,b   Wass, John A H ^c  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

^c CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Acromegaly; Cure; Diagnosis; Pegvisomant; Radiotherapy; Somatostatin analogs; Surgery

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; OCTREOTIDE; PASIREOTIDE; PEGVISOMANT; PROLACTIN; SOMATOMEDIN C; HUMAN GROWTH HORMONE;

ACROMEGALIC ARTHROPATHY; ACROMEGALY; ALBRIGHT SYNDROME; ARTHROPATHY; CARNEY COMPLEX; CARPAL TUNNEL SYNDROME; CLINICAL FEATURE; COLON CANCER; COLORECTAL TUMOR; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONVALESCENCE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; FOLLOW UP; GENE MUTATION; GLUCONEOGENESIS; GLUCOSE TRANSPORT; GROWTH HORMONE RELEASE; HEART ARRHYTHMIA; HUMAN; HYPERINSULINEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; MUSCULOSKELETAL PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL GLUCOSE TOLERANCE TEST; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; REVIEW; SEX RATIO; SLEEP DISORDERED BREATHING; STANDARDIZED MORTALITY RATIO; SURGICAL TECHNIQUE; TRANSSPHENOIDAL ADENOMECTOMY; TRANSSPHENOIDAL SURGERY; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT OBSTRUCTION; VALVULAR HEART DISEASE; VISUAL FIELD; ADENOMA; COMPLICATION; METABOLISM; PITUITARY NEOPLASMS;

ACROMEGALY; ADENOMA; HUMAN GROWTH HORMONE; HUMANS; PITUITARY NEOPLASMS;

EID: 84942616548     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-15-0109     Document Type: Review

References (210)

1. Abbassioun K, Amirjamshidi M, Mehrazin A, Khalatbary I, Keynama M, Bokai H&Abdollahi M 2006 A prospective analysis of 151 cases of patients with acromegaly operated by one neurosurgeon: a follow-up of more than 23 years. Surgical Neurology 66 26-31. (doi:10.1016/j.surneu.2005.11.063)
2. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB & Wilson CB 1998 Transsphenoidal microsurgery for growth hormonesecreting pituitary adenomas: initial outcome and long-term results. Journal of Clinical Endocrinology and Metabolism 83 3411-3418. (doi:10.1210/jcem.83.10.5111)
3. Abu Dabrh AM, Mohammed K, Asi N, Farah WH, Wang Z, Farah MH, Prokop LJ, Katznelson L&Murad MH 2014 Surgical interventions and medical treatments in treatment-naive patients with acromegaly: systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism 99 4003-4014. (doi:10.1210/jc.2014-2900)
4. Agarwal SK, Ozawa A, Mateo CM&Marx SJ 2009 The MEN1 gene and pituitary tumours. Hormone Research 71(Suppl 2) 131-138. (doi:10.1159/000192450)
5. Alexander L, Appleton D, Hall R, Ross WM&Wilkinson R 1980 Epidemiology of acromegaly in the Newcastle region. Clinical Endocrinology 12 71-79. (doi:10.1111/j.1365-2265.1980.tb03135.x)
6. Annamalai AK, Webb A, Kandasamy N, Elkhawad M, Moir S, Khan F, Maki-Petaja K, Gayton EL, Strey CH, O'Toole S et al. 2013 A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. Journal of Clinical Endocrinology and Metabolism 98 1040-1050. (doi:10.1210/jc.2012-3072)
7. Arafat AM, Mohlig M, Weickert MO, Perschel FH, Purschwitz J, Spranger J, Strasburger CJ, Schofl C&Pfeiffer AF 2008 Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. Journal of Clinical Endocrinology and Metabolism 93 1254-1262. (doi:10.1210/jc.2007-2084)
8. Attanasio R, Epaminonda P, Motti E, Giugni E, Ventrella L, Cozzi R, Farabola M, Loli P, Beck-Peccoz P&Arosio M 2003 Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study. Journal of Clinical Endocrinology and Metabolism 88 3105-3112. (doi:10.1210/jc.2002-021663)
9. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM&Bates AS 2004 Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 89 1613-1617. (doi:10.1210/jc.2003-031584)
10. Barkan AL, Beitins IZ&Kelch RP 1988 Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. Journal of Clinical Endocrinology and Metabolism 67 69-73. (doi:10.1210/jcem-67-1-69)
11. Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, van der Lely AJ&Vance ML 2005 Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. Journal of Clinical Endocrinology and Metabolism 90 5684-5691. (doi:10.1210/jc.2005-0331)
12. Barlier A, Gunz G, Zamora AJ, Morange-Ramos I, Figarella-Branger D, Dufour H, Enjalbert A&Jaquet P 1998 Prognostic and therapeutic consequences of Gsα mutations in somatotroph adenomas. Journal of Clinical Endocrinology and Metabolism 83 1604-1610.
13. Bates AS, Van't Hoff W, Jones JM&Clayton RN 1993 An audit of outcome of treatment in acromegaly. Quarterly Journal of Medicine 86 293-299.
14. Bates PR, Carson MN, Trainer PJ&Wass JA 2008 Wide variation in surgical outcomes for acromegaly in the UK. Clinical Endocrinology 68 136-142. (doi:10.1111/j.1365-2265.2007.03012.x)
15. Beauregard C, Truong U, Hardy J&Serri O 2003 Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clinical Endocrinology 58 86-91. (doi:10.1046/j.1365-2265.2003.01679.x)
16. Bengtsson BA, Eden S, Ernest I, Oden A&Sjogren B 1988 Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Medica Scandinavica 223 327-335. (doi:10.1111/j.0954-6820.1988.tb15881.x)
17. Bernabeu I, Alvarez-Escola C, Paniagua AE, Lucas T, Pavon I, Cabezas-Agricola JM, Casanueva FF&Marazuela M 2013 Pegvisomant and cabergoline combination therapy in acromegaly. Pituitary 16 101-108. (doi:10.1007/s11102-012-0382-z)
18. Bhayana S, Booth GL, Asa SL, Kovacs K&Ezzat S 2005 The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. Journal of Clinical Endocrinology and Metabolism 90 6290-6295. (doi:10.1210/jc.2005-0998)
19. Biering H, Knappe G, Gerl H&Lochs H 2000 Prevalence of diabetes in acromegaly and Cushing syndrome. Acta Medica Austriaca 27 27-31. (doi:10.1046/j.1563-2571.2000.00106.x)
20. Biermasz NR, van Dulken H&Roelfsema F 2000 Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 85 2476-2482. (doi:10.1210/jcem.85.7.6699)
21. Biermasz NR, Dekker FW, Pereira AM, van Thiel SW, Schutte PJ, van Dulken H, Romijn JA&Roelfsema F 2004 Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor Imeasurements. Journal of Clinical Endocrinology and Metabolism 89 2789-2796. (doi:10.1210/jc.2003-032041)
22. Biermasz NR, Pereira AM, Smit JW, Romijn JA&Roelfsema F 2005 Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. Journal of Clinical Endocrinology and Metabolism 90 2731-2739. (doi:10.1210/jc.2004-2297)
23. Bogazzi F, Battolla L, Spinelli C, Rossi G, Gavioli S, Di Bello V, Cosci C, Sardella C, Volterrani D, Talini E et al. 2007 Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. Journal of Clinical Endocrinology and Metabolism 92 4271-4277. (doi:10.1210/jc.2007-1213)
24. Boikos SA&Stratakis CA 2007a Molecular genetics of the cAMP-dependent protein kinase pathway and of sporadic pituitary tumorigenesis. Human Molecular Genetics 16 R80-R87. (doi:10.1093/hmg/ddm019)
25. Boikos SA&Stratakis CA 2007b Carney complex: the first 20 years. Current Opinion in Oncology 19 24-29. (doi:10.1097/CCO.0b013e32801195eb)
26. Borson-Chazot F, Garby L, Raverot G, Claustrat F, Raverot V&Sassolas G 2012 Acromegaly induced by ectopic secretion of GHRH: a review 30 years after GHRH discovery. Annales d'Endocrinologie 73 497-502. (doi:10.1016/j.ando.2012.09.004)
27. Brada M, Burchell L, Ashley S&Traish D 1999 The incidence of cerebrovascular accidents in patients with pituitary adenoma. International Journal of Radiation Oncology, Biology, Physics 45 693-698. (doi:10.1016/S0360-3016(99)00159-5)
28. Breidert M, Pinzer T, Wildbrett J, Bornstein SR&Hanefeld M 1995 Long-term effect of octreotide in acromegaly on insulin resistance. Hormone and Metabolic Research 27 226-230. (doi:10.1055/s-2007-979945)
29. Bruns C, Lewis I, Briner U, Meno-Tetang G&Weckbecker G 2002 SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. European Journal of Endocrinology 146 707-716. (doi:10.1530/eje.0.1460707)
30. van Bunderen CC, van Varsseveld NC, Baayen JC, van Furth WR, Aliaga ES, Hazewinkel MJ, Majoie CB, Freling NJ, Lips P, Fliers E et al. 2013 Predictors of endoscopic transsphenoidal surgery outcome in acromegaly: patient and tumor characteristics evaluated by magnetic resonance imaging. Pituitary 16 158-167. (doi:10.1007/s11102-012-0395-7)
31. Cain JW, Miljic D, Popovic V&Korbonits M 2010 Role of the aryl hydrocarbon receptor-interacting protein in familial isolated pituitary adenoma. Expert Review of Endocrinology&Metabolism 5 681-695. (doi:10.1586/eem.10.42)
32. Carlsen SM, Lund-Johansen M, Schreiner T, Aanderud S, Johannesen O, Svartberg J, Cooper JG, Hald JK, Fougner SL&Bollerslev J 2008 Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. Journal of Clinical Endocrinology and Metabolism 93 2984-2990. (doi:10.1210/jc.2008-0315)
33. Carmichael JD, Bonert VS, Mirocha JM&Melmed S 2009 The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 94 523-527. (doi:10.1210/jc.2008-1371)
34. Caron P, Bex M, Cullen DR, Feldt-Rasmussen U, Pico Alfonso AM, Pynka S, Racz K, Schopohl J, Tabarin A&Valimaki MJ 2004 One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clinical Endocrinology 60 734-740. (doi:10.1111/j.1365-2265.2004.02045.x)
35. Caron PJ, Bevan JS, Petersenn S, Flanagan D, Tabarin A, Prevost G, Maisonobe P&Clermont A 2014 Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. Journal of Clinical Endocrinology and Metabolism 99 1282-1290. (doi:10.1210/jc.2013-3318)
36. Cazabat L, Libè R, Perlemoine K, René-Corail F, Burnichon N, Gimenez-Roqueplo AP, Dupasquier-Fediaevsky L, Bertagna X, Clauser E, Chanson P et al. 2007 Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. European Journal of Endocrinology 157 1-7. (doi:10.1530/EJE-07-0181)
37. Cazabat L, Bouligand J, Salenave S, Bernier M, Gaillard S, Parker F, Young J, Guiochon-Mantel A&Chanson P 2012 Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients. Journal of Clinical Endocrinology and Metabolism 97 E663-E670. (doi:10.1210/jc.2011-2291)
38. Clemmons DR 2005 Quantitative measurement of IGF-I and its use in diagnosing and monitoring treatment of disorders of growth hormone secretion. Endocrine Reviews 9 55-65.
39. Clemmons DR&Van Wyk JJ 1984 Factors controlling blood concentration of somatomedin C. Clinics in Endocrinology and Metabolism 13 113-143. (doi:10.1016/S0300-595X(84)80011-0)
40. Clemmons DR, Van Wyk JJ, Ridgway EC, Kliman B, Kjellberg RN & Underwood LE 1979 Evaluation of acromegaly by radioimmunoassay of somatomedin-C. New England Journal of Medicine 301 1138-1142. (doi:10.1056/NEJM197911223012102)
41. Colao A, Ferone D, Marzullo P&Lombardi G 2004 Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocrine Reviews 25 102-152. (doi:10.1210/er.2002-0022)
42. Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ et al. 2006 Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, highdose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. European Journal of Endocrinology 154 467-477. (doi:10.1530/eje.1.02112)
43. Colao A, Auriemma RS, Lombardi G&Pivonello R 2011 Resistance to somatostatin analogs in acromegaly. Endocrine Reviews 32 247-271. (doi:10.1210/er.2010-0002)
44. Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, Fleseriu M, van der Lely AJ, Farrall AJ, Hermosillo RK et al. 2014 Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. Journal of Clinical Endocrinology and Metabolism 99 791-799. (doi:10.1210/jc.2013-2480)
45. Cordero RA&Barkan AL 2008 Current diagnosis of acromegaly. Reviews in Endocrine&Metabolic Disorders 9 13-19. (doi:10.1007/s11154-007-9060-2)
46. Costa AC, Rossi A, Martinelli CE Jr, Machado HR&Moreira AC 2002 Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure? Journal of Clinical Endocrinology and Metabolism 87 3142-3147. (doi:10.1210/jcem.87.7.8631)
47. Cozzi R, Attanasio R, Lodrini S&Lasio G 2004 Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clinical Endocrinology 61 209-215. (doi:10.1111/j.1365-2265.2004.02082.x)
48. Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P, Cortesi L&Pagani G 2006 Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. Journal of Clinical Endocrinology and Metabolism 91 1397-1403. (doi:10.1210/jc.2005-2347)
49. Cuevas-Ramos D&Fleseriu M 2014 Somatostatin receptor ligands and resistance to treatment in pituitary adenomas. Journal of Molecular Endocrinology 52 R223-R240. (doi:10.1530/JME-14-0011)
50. Daly AF, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA, Guitelman MA, Murat A, Emy P, Gimenez-Roqueplo AP, Tamburrano G et al. 2007 Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. Journal of Clinical Endocrinology and Metabolism 92 1891-1896. (doi:10.1210/jc.2006-2513)
51. Daly AF, Tichomirowa MA, Petrossians P, Heljovaara E, Jaffrain-Rea ML, Barlier A, Naves LA, Ebeling T, Karhu A, Raapana A et al. 2010 Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary denomas: an international collaborative study. Journal of Clinical Endocrinology and Metabolism E373-E383. (doi:10.1210/jc.2009-2556)
52. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA&Vandenbroucke JP 2008 Mortality in acromegaly: a meta-analysis. Journal of Clinical Endocrinology and Metabolism 93 61-67. (doi:10.1210/jc.2007-1191)
53. Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF&Barkan AL 2002 Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. Journal of Clinical Endocrinology and Metabolism 87 3537-3542. (doi:10.1210/jcem.87.8.8658)
54. Dobrashian RD, O'Halloran DJ, Hunt A, Beardwell CG&Shalet SM 1993 Relationships between insulin-like growth factor-1 levels and growth hormone concentrations during diurnal profiles and following oral glucose in acromegaly. Clinical Endocrinology 38 589-593. (doi:10.1111/j.1365-2265.1993.tb02139.x)
55. Dorward NL 2010 Endocrine outcomes in endoscopic pituitary surgery: a literature review. Acta Neurochirurgica 152 1275-1279. (doi:10.1007/s00701-010-0649-y)
56. Dreval AV, Trigolosova IV, Misnikova IV, Kovalyova YA, Tishenina RS, Barsukov IA, Vinogradova AV&Wolffenbuttel BH 2014 Prevalence of diabetes mellitus in patients with acromegaly. Endocrine Connections 3 93-98. (doi:10.1530/EC-14-0021)
57. Duncan E&Wass JA 1999 Investigation protocol: acromegaly and its investigation. Clinical Endocrinology 50 285-293. (doi:10.1046/j.1365-2265.1999.00615.x)
58. Dworakowska D, Gueorguiev M, Kelly P, Monson JP, Besser GM, Chew SL, Akker SA, Drake WM, Fairclough PD, Grossman AB et al. 2010 Repeated colonoscopic screening of patients with acromegaly: 15-year experience identifies those at risk of new colonic neoplasia and allows for effective screening guidelines. European Journal of Endocrinology 163 21-28. (doi:10.1530/EJE-09-1080)
59. Espinosa de los Monteros AL, Carrasco CA, Albarran AA, Gadelha M, Abreu A&Mercado M 2014 The role of primary pharmacological therapy in acromegaly. Pituitary 17(Suppl 1) S4-S10. (doi:10.1007/s11102-013-0530-0)
60. Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, Molitch ME, Boyd AE, Sheeler L&Cook DM 1992 Octreotide treatment of acromegaly. A randomized, multicenter study. Annals of Internal Medicine 117 711-718. (doi:10.7326/0003-4819-117-9-711)
61. Ezzat S, Forster MJ, Berchtold P, Redelmeier DA, Boerlin V&Harris AG 1994 Acromegaly. Clinical and biochemical features in 500 patients. Medicine 73 233-240. (doi:10.1097/00005792-199409000-00001)
62. Fedrizzi D&Czepielewski MA 2008 Cardiovascular disturbances in acromegaly. Arquivos Brasileiros de Endocrinologia e Metabologia 52 1416-1429. (doi:10.1590/S0004-27302008000900004)
63. Feelders RA, Bidlingmaier M, Strasburger CJ, Janssen JA, Uitterlinden P, Hofland LJ, Lamberts SW, van der Lely AJ&de Herder WW 2005 Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels. Journal of Clinical Endocrinology and Metabolism 90 6480-6489. (doi:10.1210/jc.2005-0901)
64. Fernandez A, Brada M, Zabuliene L, Karavitaki N&Wass JA 2009 Radiation-induced hypopituitarism. Endocrine-Related Cancer 16 733-772. (doi:10.1677/ERC-08-0231)
65. Fernandez A, Karavitaki N&Wass JA 2010 Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clinical Endocrinology 72 377-382. (doi:10.1111/j.1365-2265.2009.03667.x)
66. Fougner SL, Bollerslev J, Svartberg J, Oksnes M, Cooper J&Carlsen SM 2014 Preoperative octreotide treatment of acromegaly: long-term results of a randomised controlled trial. European Journal of Endocrinology 171 229-235. (doi:10.1530/EJE-14-0249)
67. Freda PU 2003 Current concepts in the biochemical assessment of the patient with acromegaly. Growth Hormone&IGF Research 13 171-184. (doi:10.1016/S1096-6374(03)00029-7)
68. Freda PU, Post KD, Powell JS&Wardlaw SL 1998a Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 83 3808-3816. (doi:10.1210/jcem.83.11.5266)
69. Freda PU, Wardlaw SL&Post KD 1998b Long-term endocrinological followup evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. Journal of Neurosurgery 89 353-358. (doi:10.3171/jns.1998.89.3.0353)
70. Freda PU, Reyes CM, Nuruzzaman AT, Sundeen RE&Bruce JN 2003 Basal and glucose-suppressed GH levels less than 1 μg/L in newly diagnosed acromegaly. Pituitary 6 175-180. (doi:10.1023/B:PITU.0000023424.72021.e2)
71. Freda PU, Nuruzzaman AT, Reyes CM, Sundeen RE&Post KD 2004 Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. Journal of Clinical Endocrinology and Metabolism 89 495-500. (doi:10.1210/jc.2003-031316)
72. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S&Rabinowitz D 2005 Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. Journal of Clinical Endocrinology and Metabolism 90 4465-4473. (doi:10.1210/jc.2005-0260)
73. Freda PU, Gordon MB, Kelepouris N, Jonsson P, Koltowska-Haggstrom M & van der Lely AJ 2014 Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from Acrostudy. Endocrine Practice 4 1-32. (doi:10.4158/EP14330.OR)
74. Friedel ME, Johnston DR, Singhal S, Al Khalili K, Farrell CJ, Evans JJ, Nyquist GG&Rosen MR 2013 Airway management and perioperative concerns in acromegaly patients undergoing endoscopic transsphenoidal surgery for pituitary tumors. Otolaryngology - Head and Neck Surgery 149 840-844. (doi:10.1177/0194599813507236)
75. Frystyk J, Freda P&Clemmons DR 2010 The current status of IGF-I assays - a 2009 update. Growth Hormone&IGF Research 20 8-18. (doi:10.1016/j.ghir.2009.09.004)
76. Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, Pronin V, Raverot G, Shimon I, Lievre KK et al. 2014 Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet. Diabetes&Endocrinology 2 875-884. (doi:10.1016/S2213-8587(14)70169-X)
77. Georgitsi M, Raitila A, Karhu A, van der Luijt RB, Aalfs CM, Sane T, Vierimaa O, Makinen MJ, Tuppurainen K, Paschke R et al. 2007 Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. Journal of Clinical Endocrinology and Metabolism 92 3321-3325. (doi:10.1210/jc.2006-2843)
78. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K&Melmed S 2000 Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism 85 526-529.
79. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K&Melmed S 2010 A consensus on criteria for cure of acromegaly. Journal of Clinical Endocrinology and Metabolism 95 3141-3148. (doi:10.1210/jc.2009-2670)
80. Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I&Melmed S 2012 Meta-analysis on the effects of octreotide on tumor mass in acromegaly.PLoS ONE 7 e36411. (doi:10.1371/journal.pone.0036411)
81. Grottoli S, Maffei P, Bogazzi F, Cannavo S, Colao A, Ghigo E, Gomez R, Graziano E, Monterubbianesi M, Jonsson P et al. 2015 ACROSTUDY: the Italian experience. Endocrine 48 334-341. (doi:10.1007/s12020-014-0393-9)
82. Hagiwara A, Inoue Y, Wakasa K, Haba T, Tashiro T&Miyamoto T 2003 Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation. Radiology 228 533-538. (doi:10.1148/radiol.2282020695)
83. Hall K, Hilding A&Thoren M 1999 Determinants of circulating insulin-like growth factor-I. Journal of Endocrinological Investigation 22 48-57. (doi:10.1007/BF03345478
84. van Haute FR, Taboada GF, Correa LL, Lima GA, Fontes R, Riello AP, Dominici M&Gadelha MR 2008 Prevalence of sleep apnea and metabolic abnormalities in patients with acromegaly and analysis of cephalometric parameters by magnetic resonance imaging. European Journal of Endocrinology 158 459-465. (doi:10.1530/EJE-07-0753)
85. Herman-Bonert VS, Zib K, Scarlett JA&Melmed S 2000 Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. Journal of Clinical Endocrinology and Metabolism 85 2958-2961. (doi:10.1210/jcem.85.8.6851)
86. Higham CE, Chung TT, Lawrance J, Drake WM&Trainer PJ 2009 Long-term experience of pegvisomant therapy as treatment for acromegaly. Clinical Endocrinology 71 86-91. (doi:10.1111/j.1365-2265.2008.03469.x)
87. Ho KY&Weissberger AJ 1994 Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy. Clinical Endocrinology 41 75-83. (doi:10.1111/j.1365-2265.1994.tb03787.x)
88. Hofland LJ&Lamberts SW 2001 Somatostatin receptor subtype expression in human tumors. Annals of Oncology 12(Suppl 2) S31-S36. (doi:10.1093/annonc/12.suppl_2.S31)
89. Holdaway IM & Rajasoorya C 1999 Epidemiology of acromegaly. Pituitary 2 29-41. (doi:10.1023/A:1009965803750)
90. Holdaway IM, Rajasoorya CR, Gamble GD&Stewart AW 2003 Long-term treatment outcome in acromegaly. Growth Hormone&IGF Research 13 185-192. (doi:10.1016/S1096-6374(03)00030-3)
91. Holdaway IM, Bolland MJ&Gamble GD 2008 A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. European Journal of Endocrinology 159 89-95. (doi:10.1530/EJE-08-0267)
92. Howlett TA, Willis D, Walker G, Wass JA & Trainer PJ 2013 Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists. Clinical Endocrinology 79 689-699. (doi:10.1111/cen.12207)
93. Igreja S, Chahal HS, King P, Bolger GB, Srirangalingham U, Guasti L, Chapple JP, Trvellin G, Gueorguiev M, Guegan K et al. 2010 Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Human Mutation 31 950-960. (doi:10.1002/humu.21292)
94. Irie M&Tsushima T 1972 Increase of serum growth hormone concentration following thyrotropin-releasing hormone injection in patients with acromegaly or gigantism. Journal of Clinical Endocrinology and Metabolism 35 97-100. (doi:10.1210/jcem-35-1-97)
95. Jacob JJ&Bevan JS 2014 Should all patients with acromegaly receive somatostatin analogue therapy before surgery and, if so, for how long? Clinical Endocrinology 81 812-817. (doi:10.1111/cen.12553)
96. Jadresic A, Banks LM, Child DF, Diamant L, Doyle FH, Fraser TR&Joplin GF 1982 The acromegaly syndrome. Relation between clinical features, growth hormone values and radiological characteristics of the pituitary tumours. Quarterly Journal of Medicine 51 189-204.
97. Jaffrain-Rea ML, Di Stefano D, Minniti G, Esposito V, Bultrini A, Ferretti E, Santoro A, Faticanti SL, Gulino A&Cantore G 2002 A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocrine-Related Cancer 9 103-113. (doi:10.1677/erc.0.0090103)
98. Jallad RS, Musolino NR, Salgado LR&Bronstein MD 2007 Treatment of acromegaly: is there still a place for radiotherapy? Pituitary 10 53-59. (doi:10.1007/s11102-007-0002-5)
99. Jane JA Jr, Starke RM, Elzoghby MA, Reames DL, Payne SC, Thorner MO, Marshall JC, Laws ER Jr&Vance ML 2011 Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome. Journal of Clinical Endocrinology and Metabolism 96 2732-2740. (doi:10.1210/jc.2011-0554)
100. Jenkins PJ, Bates P, Carson MN, Stewart PM&Wass JA 2006 Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 91 1239-1245. (doi:10.1210/jc.2005-1616)
101. Jezkova J, Marek J, Hana V, Krsek M, Weiss V, Vladyka V, Lisak R, Vymazal J & Pecen L 2006 Gamma knife radiosurgery for acromegaly - long-term experience. Clinical Endocrinology 64 588-595. (doi:10.1111/j.1365-2265.2006.02513.x)
102. Kahaly G, Olshausen KV, Mohr-Kahaly S, Erbel R, Boor S, Beyer J&Meyer J 1992 Arrhythmia profile in acromegaly. European Heart Journal 13 51-56.
103. Kaji H, Sugimoto T, Nakaoka D, Okimura Y, Kaji H, Abe H&Chihara K 2001 Bone metabolism and body composition in Japanese patients with active acromegaly. Clinical Endocrinology 55 175-181. (doi:10.1046/j.1365-2265.2001.01280.x)
104. Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M&Grossman AB 2005 Clinical review: Diagnosis and management of pituitary carcinomas. Journal of Clinical Endocrinology and Metabolism 90 3089-3099. (doi:10.1210/jc.2004-2231)
105. Karavitaki N, Botusan I, Radian S, Coculescu M, Turner HE&Wass JA 2005 The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Clinical Endocrinology 62 282-288. (doi:10.1111/j.1365-2265.2004.02191.x)
106. Karavitaki N, Turner HE, Adams CB, Cudlip S, Byrne JV, Fazal-Sanderson V, Rowlers S, Trainer PJ&Wass JA 2008 Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clinical Endocrinology 68 970-975. (doi:10.1111/j.1365-2265.2007.03139.x)
107. Karavitaki N, Fernandez A, Fazal-Sanderson V&Wass JA 2009 The value of the oral glucose tolerance test, random serum growth hormone and mean growth hormone levels in assessing the postoperative outcome of patients with acromegaly. Clinical Endocrinology 71 840-845. (doi:10.1111/j.1365-2265.2009.03578.x)
108. Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S, Kouhara H, Koga M, Saitoh Y, Ohnishi T&Arita N 2000 Impaired ß-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clinical Endocrinology 52 549-555. (doi:10.1046/j.1365-2265.2000.00986.x)
109. Kasuki L, Colli LM, Elias PC, Castro M&Gadelha MR 2012 Resistance to octreotide LAR in acromegalic patients with high SSTR2 expression: analysis of AIP expression. Arquivos Brasileiros de Endocrinologia e Metabologia 56 501-506. (doi:10.1590/S0004-27302012000800007)
110. Kasuki L, Wildemberg LE, Neto LV, Marcondes J, Takiya CM & Gadelha MR 2013 Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern. European Journal of Endocrinology 169 217-223. (doi:10.1530/EJE-13-0349)
111. Katznelson L 2010 Approach to the patient with persistent acromegaly after pituitary surgery. Journal of Clinical Endocrinology and Metabolism 95 4114-4123. (doi:10.1210/jc.2010-0670)
112. Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A & Wass JA 2014 Acromegaly: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 99 3933-3951. (doi:10.1210/jc.2014-2700)
113. Kreutzer J, Vance ML, LopesMB&Laws ER Jr 2001 Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. Journal of Clinical Endocrinology and Metabolism 86 4072-4077. (doi:10.1210/jcem.86.9.7819)
114. Krieger MD, Couldwell WT&Weiss MH 2003 Assessment of long-term remission of acromegaly following surgery. Journal of Neurosurgery 98 719-724. (doi:10.3171/jns.2003.98.4.0719)
115. Kropf LL, Madeira M, Vieira NL, Gadelha MR&de Farias ML 2013 Functional evaluation of the joints in acromegalic patients and associated factors. Clinical Rheumatology 32 991-998. (doi:10.1007/s10067-013-2219-1)
116. Lamberts SW, Uitterlinden P, Schuijff PC&Klijn JG 1988 Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical 'cure'. Clinical Endocrinology 29 411-420. (doi:10.1111/j.1365-2265.1988.tb02890.x)
117. Langsenlehner T, Stiegler C, Quehenberger F, Feigl GC, Jakse G, Mokry M, Langsenlehner U, Kapp KS&Mayer R 2007 Long-term follow-up of patients with pituitary macroadenomas after postoperative radiation therapy: analysis of tumor control and functional outcome. Strahlentherapie und Onkologie 183 241-247. (doi:10.1007/s00066-007-1706-1)
118. Larkin S, Reddy R, Karavitaki N, Cudlip S, Wass J&Ansorge O 2013 Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas. European Journal of Endocrinology 168 491-499. (doi:10.1530/EJE-12-0864)
119. Lee CC, Vance ML, Xu Z, Yen CP, Schlesinger D, Dodson B&Sheehan J 2014a Stereotactic radiosurgery for acromegaly. Journal of Clinical Endocrinology and Metabolism 99 1273-1281. (doi:10.1210/jc.2013-3743)
120. Lee CC, Vance ML, Lopes MB, Xu Z, Chen CJ&Sheehan J 2014b Stereotactic radiosurgery for acromegaly: outcomes by adenoma subtype. Pituitary 18 326-334. (doi:10.1007/s11102-014-0578-5)
121. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML et al. 2001 Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358 1754-1759. (doi:10.1016/S0140-6736(01)06844-1)
122. Le Roith D, Scavo L&Butler A 2001 What is the role of circulating IGF-I? Trends in Endocrinology and Metabolism 12 48-52. (doi:10.1016/S1043-2760(00)00349-0)
123. Li Y, Zhou LP, Ma P, Sui CG, Meng FD, Tian X, Fu LY&Jiang YH 2014 Relationship of PTTG expression with tumor invasiveness and microvessel density of pituitary adenomas: a meta-analysis. Genetic Testing and Molecular Biomarkers 18 279-285. (doi:10.1089/gtmb.2013.0447)
124. Littley MD, Shalet SM, Beardwell CG, Ahmed SR, Applegate G&SuttonML 1989 Hypopituitarism following external radiotherapy for pituitary tumours in adults. Quarterly Journal of Medicine 70 145-160.
125. Lombardi G, Colao A, Marzullo P, Biondi B, Palmieri E&Fazio S 2002 Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study. Journal of Endocrinological Investigation 25 971-976. (doi:10.1007/BF03344070)
126. Losa M&Von Werder K 1997 Pathophysiology and clinical aspects of the ectopic GH-releasing hormone syndrome. Clinical Endocrinology 47 123-135. (doi:10.1046/j.1365-2265.1997.2311048.x)
127. Losa M, Mortini P, Urbaz L, Ribotto P, Castrignano T&Giovanelli M 2006 Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates. Journal of Neurosurgery 104 899-906. (doi:10.3171/jns.2006.104.6.899)
128. Ludecke DK&Abe T 2006 Transsphenoidal microsurgery for newly diagnosed acromegaly: a personal view after more than 1,000 operations. Neuroendocrinology 83 230-239. (doi:10.1159/000095533)
129. Maiza JC, Vezzosi D, Matta M, Donadille F, Loubes-Lacroix F, Cournot M, Bennet A&Caron P 2007 Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clinical Endocrinology 67 282-289. (doi:10.1111/j.1365-2265.2007.02878.x)
130. Mao ZG, Zhu YH, Tang HL, Wang DY, Zhou J, He DS, Lan H, Luo BN & Wang HJ 2010 Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. European Journal of Endocrinology 162 661-666. (doi:10.1530/EJE-09-0908)
131. Mazziotti G&Giustina A 2010 Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary 13 60-67. (doi:10.1007/s11102-009-0169-z)
132. Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P&Giustina A 2009 Effects of somatostatin analogs on glucose homeostasis: a meta-analysis of acromegaly studies. Journal of Clinical Endocrinology and Metabolism 94 1500-1508. (doi:10.1210/jc.2008-2332)
133. Mazziotti G, Biagioli E, Maffezzoni F, Spinello M, Serra V, Maroldi R, Floriani I&Giustina A 2015 Bone turnover, bone mineral density and fracture risk in acromegaly: a meta-analysis. Journal of Clinical Endocrinology and Metabolism 100 384-394. (doi:10.1210/jc.2014-2937)
134. Melmed S 1991 Extrapituitary acromegaly. Endocrinology and Metabolism Clinics of North America 20 507-518.
135. Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D&Barkan A 2005 A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. Journal of Clinical Endocrinology and Metabolism 90 4405-4410. (doi:10.1210/jc.2004-2466)
136. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J et al. 2009 Guidelines for acromegaly management: an update. Journal of Clinical Endocrinology and Metabolism 94 1509-1517. (doi:10.1210/jc.2008-2421)
137. Melmed S, Popovic V, Bidlingmaier M, Mercado M, van der Lely AJ, Biermasz N, Bolanowski M, Coculescu M, Schopohl J, Racz K et al. 2015 Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. Journal of Clinical Endocrinology and Metabolism 100 1699-1708. (doi:10.1210/jc.2014-4113)
138. Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M et al. 2007 A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clinical Endocrinology 66 859-868. (doi:10.1111/j.1365-2265.2007.02825.x)
139. Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B et al. 2004 Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). European Journal of Endocrinology 151 439-446. (doi:10.1530/eje.0.1510439)
140. Milker-Zabel S, Debus J, Thilmann C, Schlegel W&Wannenmacher M 2001 Fractionated stereotactically guided radiotherapy and radiosurgery in the treatment of functional and nonfunctional adenomas of the pituitary gland. International Journal of Radiation Oncology, Biology, Physics 50 1279-1286. (doi:10.1016/S0360-3016(01)01535-8)
141. Miller A, Doll H, David J&Wass J 2008 Impact of musculoskeletal disease on quality of life in long-standing acromegaly. European Journal of Endocrinology 158 587-593. (doi:10.1530/EJE-07-0838)
142. Minniti G, Jaffrain-Rea ML, Osti M, Esposito V, Santoro A, Solda F, Gargiulo P, Tamburrano G&Enrici RM 2005a The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clinical Endocrinology 62 210-216. (doi:10.1111/j.1365-2265.2005.02199.x)
143. Minniti G, Traish D, Ashley S, Gonsalves A&BradaM2005b Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. Journal of Clinical Endocrinology and Metabolism 90 800-804. (doi:10.1210/jc.2004-1152)
144. Minniti G, Scaringi C, Amelio D&Maurizi ER 2012 Stereotactic irradiation of GH-secreting pituitary adenomas. International Journal of Endocrinology 2012 482861. (doi:10.1155/2012/482861)
145. Minuto FM, Resmini E, Boschetti M, Rebora A, Fazzuoli L, Arvigo M, Giusti M&Ferone D 2012 Biochemical diagnosis and assessment of disease activity in acromegaly: a two-decade experience. Pituitary 15 215-221. (doi:10.1007/s11102-011-0313-4)
146. Molitch ME 1992 Clinical manifestations of acromegaly. Endocrinology and Metabolism Clinics of North America 21 597-614.
147. Møller N, Jørgensen JO, Abildgard N, Orskov L, Schmitz O&Christiansen JS 1991 Effects of growth hormone on glucose metabolism. Hormone Research 36 32-35.
148. Mori K, Iwasaki Y, Kawasaki-Ogita Y, Honjo S, Hamamoto Y, Tatsuoka H, Fujimoto K, Ikeda H, Wada Y, Takahashi Y et al. 2013 Improvement of insulin resistance following transsphenoidal surgery in patients with acromegaly: correlation with serum IGF-I levels. Journal of Endocrinological Investigation 36 853-859. (doi:10.3275/8964)
149. Mosca S, Paolillo S, Colao A, Bossone E, Cittadini A, Iudice FL, Parente A, Conte S, Rengo G, Leosco D et al. 2013 Cardiovascular involvement in patients affected by acromegaly: an appraisal. International Journal of Cardiology 167 1712-1718. (doi:10.1016/j.ijcard.2012.11.109)
150. Muller AF, Kopchick JJ, Flyvbjerg A&van der Lely AJ 2004 Clinical review 166: Growth hormone receptor antagonists. Journal of Clinical Endocrinology and Metabolism 89 1503-1511. (doi:10.1210/jc.2002-022049)
151. Murray RD&Melmed S 2008 A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. Journal of Clinical Endocrinology and Metabolism 93 2957-2968. (doi:10.1210/jc.2008-0027)
152. Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de HerderWW & van der Lely AJ 2007 Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. Journal of Clinical Endocrinology and Metabolism 92 4598-4601. (doi:10.1210/jc.2007-1234)
153. Neggers SJ, de Herder WW, Janssen JA, Feelders RA&van der Lely AJ 2009 Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. European Journal of Endocrinology 160 529-533. (doi:10.1530/EJE-08-0843)
154. Newell-Price J 2009 Gamma knife. In Acromegaly. A Handbook of History, Current Therapy and Future Prospects, pp 169-179. Ed. John Wass. Bristol: Bio Scientifica.
155. Newman CB, Melmed S, Snyder PJ, Young WF, Boyajy LD, Levy R, Stewart WN, Klibanski A, Molitch ME&Gagel RF 1995 Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients - a clinical research center study. Journal of Clinical Endocrinology and Metabolism 80 2768-2775. (doi:10.1210/jcem.80.9.7673422)
156. Nomikos P, Buchfelder M&Fahlbusch R 2005 The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. European Journal of Endocrinology 152 379-387. (doi:10.1530/eje.1.01863)
157. Nunes VS, Correa JM, Puga ME, Silva EM&Boguszewski CL 2015 Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system. Pituitary 18 500-508. (doi:10.1007/s11102-014-0602-9)
158. Orme SM, McNally RJ, Cartwright RA&Belchetz PE 1998 Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. Journal of Clinical Endocrinology and Metabolism 83 2730-2734. (doi:10.1210/jcem.83.8.5007)
159. Pantanetti P, Sonino N, Arnaldi G&Boscaro M 2002 Self image and quality of life in acromegaly. Pituitary 5 17-19. (doi:10.1023/A:1022145116901)
160. Peacey SR, Toogood AA, Veldhuis JD, Thorner MO&Shalet SM 2001 The relationship between 24-hour growth hormone secretion and insulinlike growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy. Journal of Clinical Endocrinology and Metabolism 86 259-266. (doi:10.1210/jcem.86.1.7154)
161. Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Hofler H, Fend F, Graw J&Atkinson MJ 2006 Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. PNAS 103 15558-15563. (doi:10.1073/pnas.0603877103)
162. Pereira AM, van Thiel SW, Lindner JR, Roelfsema F, van der Wall EE, Morreau H, Smit JW, Romijn JA&Bax JJ 2004 Increased prevalence of regurgitant valvular heart disease in acromegaly. Journal of Clinical Endocrinology and Metabolism 89 71-75. (doi:10.1210/jc.2003-030849)
163. Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho YY, Hu K, Farrall AJ et al. 2010 Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. Journal of Clinical Endocrinology and Metabolism 95 2781-2789. (doi:10.1210/jc.2009-2272)
164. Petersenn S, Farrall AJ, De Block C, Melmed S, Schopohl J, Caron P, Cuneo R, Kleinberg D, Colao A, Ruffin M et al. 2014a Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, phase II extension study. Pituitary 17 132-140. (doi:10.1007/s11102-013-0478-0)
165. Petersenn S, Bollerslev J, Arafat AM, Schopohl J, Serri O, Katznelson L, Lasher J, Hughes G, Hu K, Shen G et al. 2014b Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study. Journal of Clinical Pharmacology 54 1308-1317. (doi:10.1002/jcph.326)
166. Petrovich Z, Jozsef G, Yu C&Apuzzo ML 2003 Radiotherapy and stereotactic radiosurgery for pituitary tumors. Neurosurgery Clinics of North America 14 147-166. (doi:10.1016/S1042-3680(02)00031-1)
167. Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE&Trainer PJ 2007 Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clinical Endocrinology 67 65-70. (doi:10.1111/j.1365-2265.2007.02836.x)
168. Pollock BE, Nippoldt TB, Stafford SL, Foote RL&Abboud CF 2002 Results of stereotactic radiosurgery in patients with hormone-producing pituitary adenomas: factors associated with endocrine normalization. Journal of Neurosurgery 97 525-530. (doi:10.3171/jns.2002.97.3.0525)
169. Puder JJ, Nilavar S, Post KD&Freda PU 2005 Relationship between diseaserelated morbidity and biochemical markers of activity in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 90 1972-1978. (doi:10.1210/jc.2004-2009)
170. Puig-Domingo M, Resmini E, Gomez-Anson B, Nicolau J, Mora M, Palomera E, Marti C, Halperin I&Webb SM 2010 Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. Journal of Clinical Endocrinology and Metabolism 95 4973-4978. (doi:10.1210/jc.2010-0573)
171. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ&Ibbertson HK 1994 Determinants of clinical outcome and survival in acromegaly. Clinical Endocrinology 41 95-102. (doi:10.1111/j.1365-2265.1994.tb03789.x)
172. Ramirez C, Vargas G, Gonzalez B, Grossman A, Rabago J, Sosa E, Espinosade-Los-Monteros AL&Mercado M 2012 Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying? European Journal of Endocrinology 166 21-26. (doi:10.1530/EJE-11-0738)
173. Reddy R, Hope S&Wass J 2010 Acromegaly. BMJ 341 c4189. (doi:10.1136/bmj.c4189)
174. Reid TJ, Post KD, Bruce JN, Nabi KM, Reyes-Vidal CM&Freda PU 2010 Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and underdiagnosed. Clinical Endocrinology 72 203-208. (doi:10.1111/j.1365-2265.2009.03626.x)
175. Reimondo G, Bondanelli M, Ambrosio MR, Grimaldi F, Zaggia B, Zatelli MC, Allasino B, Laino F, Aroasio E, Termine A et al. 2014 Growth hormone values after an oral glucose load do not add clinically useful information in patients with acromegaly on long-term somatostatin receptor ligand treatment. Endocrine 45 122-127. (doi:10.1007/s12020-013-9996-9)
176. Renehan AG, O'Dwyer ST&Shalet SM 2001 Screening colonoscopy for acromegaly in perspective. Clinical Endocrinology 55 731-733. (doi:10.1046/j.1365-2265.2001.01355.x)
177. Renehan AG, O'Connell J, O'Halloran D, Shanahan F, Potten CS, O'Dwyer ST&Shalet SM 2003 Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications. Hormone and Metabolic Research 35 712-725. (doi:10.1055/s-2004-814150)
178. Roelfsema F, Biermasz NR&Pereira AM 2012 Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary 15 71-83. (doi:10.1007/s11102-011-0347-7)
179. Roemmler J, Gutt B, Fischer R, Vay S, Wiesmeth A, Bidlingmaier M, Schopohl J&Angstwurm M 2012 Elevated incidence of sleep apnoea in acromegaly-correlation to disease activity. Sleep&Breathing 16 1247-1253. (doi:10.1007/s11325-011-0641-7)
180. Rokkas T, Pistiolas D, Sechopoulos P, Margantinis G&Koukoulis G 2008 Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis. World Journal of Gastroenterology 14 3484-3489. (doi:10.3748/wjg.14.3484)
181. Samson SL&Ezzat S 2014 AACE/ACE disease state clinical review: dopamine agonists for hyperprolactinemia and the risk of cardiac valve disease. Endocrine Practice 20 608-616. (doi:10.4158/EP14148.RA)
182. Sandret L, Maison P&Chanson P 2011 Place of cabergoline in acromegaly: a meta-analysis. Journal of Clinical Endocrinology and Metabolism 96 1327-1335. (doi:10.1210/jc.2010-2443)
183. Sarkar S, Chacko AG&Chacko G 2014 An analysis of granulation patterns, MIB-1 proliferation indices and p53 expression in 101 patients with acromegaly. Acta Neurochirurgica 156 2221-2230. (doi:10.1007/s00701-014-2230-6)
184. Schofl C, Franz H, Grussendorf M, Honegger J, Jaursch-Hancke C, Mayr B & Schopohl J 2013 Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register. European Journal of Endocrinology 168 39-47. (doi:10.1530/EJE-12-0602)
185. Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B & Strasburger CJ 2007 Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. European Journal of Endocrinology 156 75-82. (doi:10.1530/eje.1.02312)
186. Serri O, Beauregard C&Hardy J 2004 Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 89 658-661. (doi:10.1210/jc.2003-030915)
187. Shen M, Shou X, Wang Y, Zhang Z, Wu J, Mao Y, Li S&Zhao Y 2010 Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study. Endocrine Journal 57 1035-1044. (doi:10.1507/endocrj.K10E-203)
188. Sherlock M, Fernandez-Rodriguez E, Alonso AA, Reulen RC, Ayuk J, Clayton RN, Holder G, Sheppard MC, Bates A&Stewart PM 2009 Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues. Journal of Clinical Endocrinology and Metabolism 94 1255-1263. (doi:10.1210/jc.2008-1420)
189. Sherlock M, Ayuk J, Tomlinson JW, Toogood AA, Aragon-Alonso A, Sheppard MC, Bates AS&Stewart PM 2010 Mortality in patients with pituitary disease. Endocrine Reviews 31 301-342. (doi:10.1210/er.2009-0033)
190. Stapleton CJ, Liu CY & Weiss MH 2010 The role of stereotactic radiosurgery in themultimodalmanagement of growth hormone-secreting pituitary adenomas. Neurosurgical Focus29E11. (doi:10.3171/2010.7.FOCUS10159)
191. Starke RM, Raper DM, Payne SC, Vance ML, Oldfield EH&Jane JA Jr 2013 Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. Journal of Clinical Endocrinology and Metabolism 98 3190-3198. (doi:10.1210/jc.2013-1036)
192. Stone JC, Clark J, Cuneo R, Russell AW&Doi SA 2014 Estrogen and selective estrogen receptor modulators (SERMs) for the treatment of acromegaly: a meta-analysis of published observational studies. Pituitary 17 284-295. (doi:10.1007/s11102-013-0504-2)
193. Stratakis CA&Horvath A 1993 Carney complex. In Gene Reviews. Eds RA Pagon, MP Adam&TD Bird. Seattle, WA, USA: University of Washington.
194. Sun H, Brzana J, Yedinak CG, Gultekin SH, Delashaw JB&Fleseriu M 2014 Factors associated with biochemical remission after microscopic transsphenoidal surgery for acromegaly. Journal of Neurological Surgery. Part B, Skull Base 75 47-52. (doi:10.1055/s-0033-1354578)
195. Swearingen B, Barker FG, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM&Zervas NT 1998 Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism 83 3419-3426.
196. Tabaee A, Anand VK, Barron Y, Hiltzik DH, Brown SM, Kacker A, Mazumdar M&Schwartz TH 2009 Endoscopic pituitary surgery: a systematic review and meta-analysis. Journal of Neurosurgery 111 545-554. (doi:10.3171/2007.12.17635)
197. Tan KC, Shiu SW, Janus ED&Lam KS 1997 LDL subfractions in acromegaly: relation to growth hormone and insulin-like growth factor-I. Atherosclerosis 129 59-65. (doi:10.1016/S0021-9150(96)06015-7)
198. Terzolo M, Reimongo G, Gasperi M, Cozzi R, Pivonello R, Vitale G, Scillitani A, Attanasio R, Cecconi E, Daffara F et al. 2005 Colonoscopic screening and follow-up in patients with acromegaly: a multicenter study in Italy. Journal of Clinical Endocrinology and Metabolism 90 84-90. (doi:10.1210/jc.2004-0240)
199. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML et al.2000 Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine 342 1171-1177. (doi:10.1056/NEJM200004203421604)
200. Trotman-Dickenson B, Weetman AP&Hughes JM 1991 Upper airflow obstruction and pulmonary function in acromegaly: relationship to disease activity. Quarterly Journal of Medicine 79 527-538.
201. Urbani C, Sardella C, Calevro A, Rossi G, Scattina I, Lombardi M, Lupi I, Manetti L, Martino E&Bogazzi F 2013 Effects of medical therapies for acromegaly on glucose metabolism. European Journal of Endocrinology 169 99-108. (doi:10.1530/EJE-13-0032)
202. Wass JA 1997 Growth hormone, insulin-like growth factor-I and its binding proteins in the follow-up of acromegaly. Journal of Endocrinology 155(Suppl 1) S17-S19.
203. Wass J 2005 Debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogues. European Journal of Endocrinology 152 693-694. (doi:10.1530/eje.1.01896)
204. Webb SM 2006 Quality of life in acromegaly. Neuroendocrinology 83 224-229. (doi:10.1159/000095532)
205. Webb SM, Casanueva F&Wass JA 2002 Oncological complications of excess GH in acromegaly. Pituitary 5 21-25. (doi:10.1023/A:1022149300972)
206. Weinstein LS, Yu S, Warner DR&Liu J 2001 Endocrine manifestations of stimulatory G protein α-subunit mutations and the role of genomic imprinting. Endocrine Reviews 22 675-705. (doi:10.1210/edrv.22.5.0439)
207. Wilson PJ, De Loyde KJ, Williams JR&Smee RI 2013 Acromegaly: a single centre's experience of stereotactic radiosurgery and radiotherapy for growth hormone secreting pituitary tumours with the linear accelerator. Journal of Clinical Neuroscience 20 1506-1513. (doi:10.1016/j.jocn.2012.11.026)
208. Wolinski K, Czarnywojtek A&Ruchala M 2014 Risk of thyroid nodular disease and thyroid cancer in patients with acromegaly - meta-analysis and systematic review. PLoS ONE 9 e88787. (doi:10.1371/journal.pone.0088787)
209. Yarman S, Kurtulmus N, Canbolat A, Bayindir C, Bilgic B&Ince N 2010 Expression of Ki-67, p53 and vascular endothelial growth factor (VEGF) concomitantly in growth hormone-secreting pituitary adenomas; which one has a role in tumor behavior? Neuroendocrinology Letters 31 823-828.
210. Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, BronsteinMD & Melmed S 1999 Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 84 761-767. (doi:10.1210/jcem.84.2.5432)